Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies-Reference-Cited by-同舟云学术

Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies

Published:2019-09-23 Issue:6 Volume:84 Page:1289-1301
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Appleman Leonard J.^ORCID,Beumer Jan H.,Jiang Yixing,Lin Yan,Ding Fei,Puhalla Shannon,Swartz Leigh,Owonikoko Taofeek K.,Donald Harvey R.,Stoller Ronald,Petro Daniel P.,Tawbi Hussein A.,Argiris Athanassios,Strychor Sandra,Pouquet Marie,Kiesel Brian,Chen Alice P.,Gandara David,Belani Chandra P.,Chu Edward,Ramalingam Suresh S.

Funder

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-019-03960-w.pdf

Reference50 articles.

1. Ray Chaudhuri A, Nussenzweig A (2017) The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol 18:610. https://doi.org/10.1038/nrm.2017.53

2. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035):913–917. https://doi.org/10.1038/nature03443

3. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917–921